Major Trials with Major Impact: Compass Trial


Dr Pankaj Jariwala, Hyderabad    04 January 2018

  1. No significant benefit of rivaroxaban alone.
  2. In patients with established stable atherosclerotic disease, rivaroxaban + aspirin resulted in a modest 1.3% absolute risk reduction in CV death, stroke or nonfatal MI, with a trend toward improved mortality. This benefit was offset by a 1.2% increased absolute risk in major bleeding.


  1. Exclusion of 2,320 participants after run-in period (due to failure to adhere/tolerate) raises possibility of selection bias and decreased generalizability.
  2. Study terminated early due to efficacy of rivaroxaban + aspirin vs. aspirin alone. Thus, the study may overestimate the degree of benefit of rivaroxaban + aspirin and potentially underestimate the degree of increased bleeding with this therapy.
  3. The lack of statistical significance of the observed trend towards improved mortality with combination rivaroxaban + aspirin may be due to underpowering for this outcome.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.